This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

MLN1021

Takeda Pharmaceutical Company Ltd

Drug Names(s): MLN1021

Description: MLN1021 is an oral anticoagulant being developed for the prevention of clinically significant blood clots both in patients with venous thromboembolic disease and in patients with atrial fibrillation at risk for stroke.

Deal Structure: MLN1021 was originally developed by Millennium.

In April 2008, Takeda Pharmaceutical and Millennium Pharmaceuticals announced that they entered into a definitive agreement pursuant to which Takeda will acquire Millennium for approximately $8.8 billion through a cash tender offer of $25.00 per share. The acquisition closed in May 2008.


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug